TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Automated Clinical Reminders in the Care of Chronic Kidney Disease Patients
Brief Summary: To determine whether the use of educational sessions and computerized clinical reminders can improve primary care doctors' delivery of care to CKD patients compared to educational sessions alone. Hypothesis: Clinical reminders will improve the care delivered to CKD patients


Options:
A: Arm Label: Controls ("not tested"); Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention ("tested"); Type: ACTIVE_COMPARATOR; Interventions: Genetic: Pharmacogenetic testing | Intervention Type: GENETIC; Name: Pharmacogenetic testing; Assigned to Arm(s): Intervention ("tested")
B: Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: STAR - Study of Technology to Accelerate Research | Arm Label: Clinician intervention only; Type: EXPERIMENTAL; Interventions: Behavioral: STAR - Study of Technology to Accelerate Research | Arm Label: Clinician intervention plus Direct-to-parent communication; Type: EXPERIMENTAL; Interventions: Behavioral: STAR - Study of Technology to Accelerate Research | Intervention Type: BEHAVIORAL; Name: STAR - Study of Technology to Accelerate Research; Assigned to Arm(s): Clinician intervention only, Clinician intervention plus Direct-to-parent communication, Usual Care
C: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: Driving in Mild Dementia Decision Tool | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Driving in Mild Dementia Decision Tool; Assigned to Arm(s): Intervention
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: automated clinical alerts, Other: provider education | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: provider education | Intervention Type: OTHER; Name: automated clinical alerts; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: provider education; Assigned to Arm(s): 1, 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Automated Clinical Reminders in the Care of Chronic Kidney Disease Patients
Brief Summary: To determine whether the use of educational sessions and computerized clinical reminders can improve primary care doctors' delivery of care to CKD patients compared to educational sessions alone. Hypothesis: Clinical reminders will improve the care delivered to CKD patients


Options:
A: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: iChoose Kidney Decision Aid; Type: EXPERIMENTAL; Interventions: Behavioral: iChoose Kidney Decision Aid | Intervention Type: BEHAVIORAL; Name: iChoose Kidney Decision Aid; Assigned to Arm(s): iChoose Kidney Decision Aid
B: Arm Label: Multi-component Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Action-focused problem-solving, Device: Electronic pillbox monitoring, dose reminders, and feedback | Arm Label: Attention control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Action-focused problem-solving; Assigned to Arm(s): Multi-component Intervention | Intervention Type: DEVICE; Name: Electronic pillbox monitoring, dose reminders, and feedback; Assigned to Arm(s): Multi-component Intervention
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: automated clinical alerts, Other: provider education | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: provider education | Intervention Type: OTHER; Name: automated clinical alerts; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: provider education; Assigned to Arm(s): 1, 2
D: Arm Label: Telehome Monitoring; Type: EXPERIMENTAL; Interventions: Device: Telehome Monitoring | Arm Label: Standard of Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Telehome Monitoring; Assigned to Arm(s): Telehome Monitoring

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Automated Clinical Reminders in the Care of Chronic Kidney Disease Patients
Brief Summary: To determine whether the use of educational sessions and computerized clinical reminders can improve primary care doctors' delivery of care to CKD patients compared to educational sessions alone. Hypothesis: Clinical reminders will improve the care delivered to CKD patients


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: automated clinical alerts, Other: provider education | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: provider education | Intervention Type: OTHER; Name: automated clinical alerts; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: provider education; Assigned to Arm(s): 1, 2
B: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Attention control | Arm Label: B; Type: EXPERIMENTAL; Interventions: Behavioral: Intervention | Intervention Type: BEHAVIORAL; Name: Attention control; Assigned to Arm(s): A | Intervention Type: BEHAVIORAL; Name: Intervention; Assigned to Arm(s): B
C: Arm Label: TALK Plus; Type: EXPERIMENTAL; Interventions: Behavioral: TALK PLUS | Arm Label: TALK Standard; Type: EXPERIMENTAL; Interventions: Behavioral: TALK Standard | Arm Label: Usual Care; Type: OTHER; Interventions: Behavioral: Usual Care | Intervention Type: BEHAVIORAL; Name: TALK PLUS; Assigned to Arm(s): TALK Plus | Intervention Type: BEHAVIORAL; Name: TALK Standard; Assigned to Arm(s): TALK Standard | Intervention Type: BEHAVIORAL; Name: Usual Care; Assigned to Arm(s): Usual Care
D: Arm Label: Pharmacist intervention; Type: EXPERIMENTAL; Interventions: Other: Pharmacist based QI program | Arm Label: Control - usual care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Intervention Type: OTHER; Name: Pharmacist based QI program; Assigned to Arm(s): Pharmacist intervention | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Control - usual care

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Combined Sono-electro-magnetic Therapy for Treatment of Refractory Chronic Pelvic Pain Syndrome: A Prospective, Randomized, Double-blind, Placebo-controlled Trial
Brief Summary: Treatment of chronic pelvic pain syndrome (CPPS) is challenging for patients and physicians once conventional therapies fail.

We hypothesize that combined sono-electro-magnetic therapy can improve refractory CPPS in men. In addition, we postulate that combined sono-electro-magnetic therapy as well as placebo therapy has a significant effect on brain activity detectable by functional MRI.


Options:
A: Arm Label: Placebo Arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: dustasteride arm; Type: EXPERIMENTAL; Interventions: Drug: Dutasteride | Intervention Type: DRUG; Name: Dutasteride; Assigned to Arm(s): dustasteride arm | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Arm
B: Arm Label: Acupuncture; Type: EXPERIMENTAL; Interventions: Device: Acupuncture | Arm Label: placebo needle; Type: PLACEBO_COMPARATOR; Interventions: Device: placebo needle | Intervention Type: DEVICE; Name: Acupuncture; Assigned to Arm(s): Acupuncture | Intervention Type: DEVICE; Name: placebo needle; Assigned to Arm(s): placebo needle
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: combined sono-electro-magnetic therapy (Sonodyn Medico Star) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Device: placebo therapy (Placebo Sonodyn Medico Star) | Intervention Type: DEVICE; Name: combined sono-electro-magnetic therapy (Sonodyn Medico Star); Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: placebo therapy (Placebo Sonodyn Medico Star); Assigned to Arm(s): 2
D: Intervention Type: PROCEDURE; Name: Acupuncture; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Combined Sono-electro-magnetic Therapy for Treatment of Refractory Chronic Pelvic Pain Syndrome: A Prospective, Randomized, Double-blind, Placebo-controlled Trial
Brief Summary: Treatment of chronic pelvic pain syndrome (CPPS) is challenging for patients and physicians once conventional therapies fail.

We hypothesize that combined sono-electro-magnetic therapy can improve refractory CPPS in men. In addition, we postulate that combined sono-electro-magnetic therapy as well as placebo therapy has a significant effect on brain activity detectable by functional MRI.


Options:
A: Intervention Type: PROCEDURE; Name: Acupuncture; Assigned to Arm(s): N/A
B: Arm Label: Placebo Arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: dustasteride arm; Type: EXPERIMENTAL; Interventions: Drug: Dutasteride | Intervention Type: DRUG; Name: Dutasteride; Assigned to Arm(s): dustasteride arm | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Arm
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: combined sono-electro-magnetic therapy (Sonodyn Medico Star) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Device: placebo therapy (Placebo Sonodyn Medico Star) | Intervention Type: DEVICE; Name: combined sono-electro-magnetic therapy (Sonodyn Medico Star); Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: placebo therapy (Placebo Sonodyn Medico Star); Assigned to Arm(s): 2
D: Arm Label: Acupuncture; Type: EXPERIMENTAL; Interventions: Device: Acupuncture | Arm Label: placebo needle; Type: PLACEBO_COMPARATOR; Interventions: Device: placebo needle | Intervention Type: DEVICE; Name: Acupuncture; Assigned to Arm(s): Acupuncture | Intervention Type: DEVICE; Name: placebo needle; Assigned to Arm(s): placebo needle

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-Blind, Phase 3 Study of the Safety and Efficacy of Emulsion Formulation U0267, Versus Vehicle in Subjects With Plaque-type Psoriasis
Brief Summary: The purpose of the study is to demonstrate the safety and efficacy of U0267 in subjects with plaque-type psoriasis.


Options:
A: Intervention Type: DRUG; Name: Vehicle (Placebo) applied BID; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: QRX-101 75 mcg/g ointment applied QD; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: QRX-101 75 mcg/g ointment applied BID; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: LCD | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: calcipotriol | Intervention Type: DRUG; Name: LCD; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: calcipotriol; Assigned to Arm(s): 2
C: Arm Label: U0267 Foam; Type: EXPERIMENTAL; Interventions: Drug: U0267 | Arm Label: Vehicle foam; Type: PLACEBO_COMPARATOR; Interventions: Drug: Vehicle | Intervention Type: DRUG; Name: U0267; Assigned to Arm(s): U0267 Foam | Intervention Type: DRUG; Name: Vehicle; Assigned to Arm(s): Vehicle foam
D: Arm Label: Group 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: WBI-1001 | Arm Label: Group 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: WBI-1001 | Intervention Type: DRUG; Name: WBI-1001; Assigned to Arm(s): Group 1, Group 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Antibiotics in Patients With Acute Respiratory Tract Infections in Primary Care in Consideration of Procalcitonin as Additive Parameter
Brief Summary: Antibiotics in patients with acute respiratory tract infections in primary care in consideration of procalcitonin as additive parameter.

The purpose of this study is to compare the ordinary manner of antibiotic- prescription with the prescription in consideration of procalcitonin-value in patients with acute respiratory tract infections.


Options:
A: Arm Label: DECISION+ Program; Type: EXPERIMENTAL; Interventions: Behavioral: Decision+ program (to improve optimal drug prescription for ARI) | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Decision+ program (to improve optimal drug prescription for ARI); Assigned to Arm(s): DECISION+ Program
B: Arm Label: C-reactive protein test; Type: EXPERIMENTAL; Interventions: Device: C-reactive protein test | Intervention Type: DEVICE; Name: C-reactive protein test; Assigned to Arm(s): C-reactive protein test
C: Intervention Type: BEHAVIORAL; Name: No antibiotics if se-procalcitonin is below stated limit; Assigned to Arm(s): N/A
D: Intervention Type: OTHER; Name: laboratory value procalcitonin; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Antibiotics in Patients With Acute Respiratory Tract Infections in Primary Care in Consideration of Procalcitonin as Additive Parameter
Brief Summary: Antibiotics in patients with acute respiratory tract infections in primary care in consideration of procalcitonin as additive parameter.

The purpose of this study is to compare the ordinary manner of antibiotic- prescription with the prescription in consideration of procalcitonin-value in patients with acute respiratory tract infections.


Options:
A: Arm Label: PCT; Type: EXPERIMENTAL; Interventions: Behavioral: a strategy based on PCT guided AB therapy | Arm Label: Guidelines; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: a strategy based on PCT guided AB therapy | Intervention Type: BEHAVIORAL; Name: a strategy based on PCT guided AB therapy; Assigned to Arm(s): Guidelines, PCT
B: Intervention Type: BEHAVIORAL; Name: No antibiotics if se-procalcitonin is below stated limit; Assigned to Arm(s): N/A
C: Intervention Type: OTHER; Name: laboratory value procalcitonin; Assigned to Arm(s): N/A
D: N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Antibiotics in Patients With Acute Respiratory Tract Infections in Primary Care in Consideration of Procalcitonin as Additive Parameter
Brief Summary: Antibiotics in patients with acute respiratory tract infections in primary care in consideration of procalcitonin as additive parameter.

The purpose of this study is to compare the ordinary manner of antibiotic- prescription with the prescription in consideration of procalcitonin-value in patients with acute respiratory tract infections.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: Procalcitonin guided strategy | Intervention Type: PROCEDURE; Name: Procalcitonin guided strategy; Assigned to Arm(s): 1
B: Intervention Type: BEHAVIORAL; Name: No antibiotics if se-procalcitonin is below stated limit; Assigned to Arm(s): N/A
C: Intervention Type: OTHER; Name: laboratory value procalcitonin; Assigned to Arm(s): N/A
D: Arm Label: Group 1 - C-reactive protein (CRP) guided ab therapy; Type: EXPERIMENTAL; Interventions: Other: C-reactive protein guided antibiotic therapy | Arm Label: Group 2 - procalcitonin (PCT) guided ab therapy; Type: ACTIVE_COMPARATOR; Interventions: Other: Procalcitonin guided antibiotic therapy | Intervention Type: OTHER; Name: C-reactive protein guided antibiotic therapy; Assigned to Arm(s): Group 1 - C-reactive protein (CRP) guided ab therapy | Intervention Type: OTHER; Name: Procalcitonin guided antibiotic therapy; Assigned to Arm(s): Group 2 - procalcitonin (PCT) guided ab therapy

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Infliximab for the Prevention of Recurrent Crohn's Disease After Surgery
Brief Summary: A randomized, placebo-controlled pilot study to determine endoscopic recurrence of Crohn's disease 12 months after curative, resective ileal or ileocolonic surgery in patients receiving post-operative infliximab or placebo


Options:
A: Arm Label: Infliximab; Type: EXPERIMENTAL; Interventions: Biological: Infliximab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: BIOLOGICAL; Name: Infliximab; Assigned to Arm(s): Infliximab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: infliximab | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: infliximab; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2
C: Arm Label: CT-P13 - CT-P13; Type: EXPERIMENTAL; Interventions: Biological: CT-P13 | Arm Label: CT-P13 - Remicade; Type: ACTIVE_COMPARATOR; Interventions: Biological: CT-P13, Biological: Remicade | Arm Label: Remicade - Remicade; Type: ACTIVE_COMPARATOR; Interventions: Biological: Remicade | Arm Label: Remicade - CT-P13; Type: EXPERIMENTAL; Interventions: Biological: CT-P13, Biological: Remicade | Intervention Type: BIOLOGICAL; Name: CT-P13; Assigned to Arm(s): CT-P13 - CT-P13, CT-P13 - Remicade, Remicade - CT-P13 | Intervention Type: BIOLOGICAL; Name: Remicade; Assigned to Arm(s): CT-P13 - Remicade, Remicade - CT-P13, Remicade - Remicade
D: Arm Label: Cohort 1: CT-P13 IV 5 mg/kg; Type: ACTIVE_COMPARATOR; Interventions: Biological: CT-P13 | Arm Label: Cohort 2: CT-P13 SC 120 mg; Type: EXPERIMENTAL; Interventions: Biological: CT-P13 | Arm Label: Cohort 3: CT-P13 SC 180 mg; Type: EXPERIMENTAL; Interventions: Biological: CT-P13 | Arm Label: Cohort 4: CT-P13 SC 240 mg; Type: EXPERIMENTAL; Interventions: Biological: CT-P13 | Arm Label: Arm 1: CT-P13 SC 120/240 mg; Type: EXPERIMENTAL; Interventions: Biological: CT-P13 | Arm Label: Arm 2: CT-P13 IV 5 mg/kg; Type: ACTIVE_COMPARATOR; Interventions: Biological: CT-P13 | Intervention Type: BIOLOGICAL; Name: CT-P13; Assigned to Arm(s): Cohort 1: CT-P13 IV 5 mg/kg | Intervention Type: BIOLOGICAL; Name: CT-P13; Assigned to Arm(s): Cohort 2: CT-P13 SC 120 mg | Intervention Type: BIOLOGICAL; Name: CT-P13; Assigned to Arm(s): Cohort 3: CT-P13 SC 180 mg | Intervention Type: BIOLOGICAL; Name: CT-P13; Assigned to Arm(s): Cohort 4: CT-P13 SC 240 mg | Intervention Type: BIOLOGICAL; Name: CT-P13; Assigned to Arm(s): Arm 1: CT-P13 SC 120/240 mg | Intervention Type: BIOLOGICAL; Name: CT-P13; Assigned to Arm(s): Arm 2: CT-P13 IV 5 mg/kg

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Infliximab for the Prevention of Recurrent Crohn's Disease After Surgery
Brief Summary: A randomized, placebo-controlled pilot study to determine endoscopic recurrence of Crohn's disease 12 months after curative, resective ileal or ileocolonic surgery in patients receiving post-operative infliximab or placebo


Options:
A: Arm Label: Double Blind; Type: PLACEBO_COMPARATOR; Interventions: Biological: adalimumab, Biological: placebo | Arm Label: Open Label; Type: OTHER; Interventions: Biological: adalimumab | Intervention Type: BIOLOGICAL; Name: adalimumab; Assigned to Arm(s): Double Blind | Intervention Type: BIOLOGICAL; Name: placebo; Assigned to Arm(s): Double Blind | Intervention Type: BIOLOGICAL; Name: adalimumab; Assigned to Arm(s): Open Label
B: Arm Label: Tight Control Management; Type: EXPERIMENTAL; Interventions: Biological: Adalimumab, Drug: Prednisone, Drug: Azathioprine | Arm Label: Clinically Driven Management; Type: ACTIVE_COMPARATOR; Interventions: Biological: Adalimumab, Drug: Prednisone, Drug: Azathioprine | Intervention Type: BIOLOGICAL; Name: Adalimumab; Assigned to Arm(s): Clinically Driven Management, Tight Control Management | Intervention Type: DRUG; Name: Prednisone; Assigned to Arm(s): Clinically Driven Management, Tight Control Management | Intervention Type: DRUG; Name: Azathioprine; Assigned to Arm(s): Clinically Driven Management, Tight Control Management
C: Arm Label: Systematic azathioprine group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Azathioprine, Procedure: Ileocolonoscopy, Procedure: Small bowel follow trough | Arm Label: Endoscopy-driven azathioprine group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Azathioprine in case of endoscopic recurrence, Procedure: Ileocolonoscopy, Procedure: Small bowel follow trough | Intervention Type: DRUG; Name: Azathioprine; Assigned to Arm(s): Systematic azathioprine group | Intervention Type: DRUG; Name: Azathioprine in case of endoscopic recurrence; Assigned to Arm(s): Endoscopy-driven azathioprine group | Intervention Type: PROCEDURE; Name: Ileocolonoscopy; Assigned to Arm(s): Endoscopy-driven azathioprine group, Systematic azathioprine group | Intervention Type: PROCEDURE; Name: Small bowel follow trough; Assigned to Arm(s): Endoscopy-driven azathioprine group, Systematic azathioprine group
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: infliximab | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: infliximab; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Infliximab for the Prevention of Recurrent Crohn's Disease After Surgery
Brief Summary: A randomized, placebo-controlled pilot study to determine endoscopic recurrence of Crohn's disease 12 months after curative, resective ileal or ileocolonic surgery in patients receiving post-operative infliximab or placebo


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: infliximab | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: infliximab; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2
B: Arm Label: Azathioprine; Type: EXPERIMENTAL; Interventions: Drug: Azathioprine, Drug: Mesalazine placebo | Arm Label: Mesalazine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mesalazine, Drug: Azathioprine placebo | Intervention Type: DRUG; Name: Azathioprine; Assigned to Arm(s): Azathioprine | Intervention Type: DRUG; Name: Mesalazine; Assigned to Arm(s): Mesalazine | Intervention Type: DRUG; Name: Azathioprine placebo; Assigned to Arm(s): Mesalazine | Intervention Type: DRUG; Name: Mesalazine placebo; Assigned to Arm(s): Azathioprine
C: Arm Label: Systematic azathioprine group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Azathioprine, Procedure: Ileocolonoscopy, Procedure: Small bowel follow trough | Arm Label: Endoscopy-driven azathioprine group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Azathioprine in case of endoscopic recurrence, Procedure: Ileocolonoscopy, Procedure: Small bowel follow trough | Intervention Type: DRUG; Name: Azathioprine; Assigned to Arm(s): Systematic azathioprine group | Intervention Type: DRUG; Name: Azathioprine in case of endoscopic recurrence; Assigned to Arm(s): Endoscopy-driven azathioprine group | Intervention Type: PROCEDURE; Name: Ileocolonoscopy; Assigned to Arm(s): Endoscopy-driven azathioprine group, Systematic azathioprine group | Intervention Type: PROCEDURE; Name: Small bowel follow trough; Assigned to Arm(s): Endoscopy-driven azathioprine group, Systematic azathioprine group
D: Arm Label: Metronidazole + Azathioprine.; Type: EXPERIMENTAL; Interventions: Drug: Metronidazole, Drug: Azathioprine | Arm Label: Metronidazole + Adalimumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metronidazole, Drug: Adalimumab | Intervention Type: DRUG; Name: Metronidazole; Assigned to Arm(s): Metronidazole + Azathioprine. | Intervention Type: DRUG; Name: Metronidazole; Assigned to Arm(s): Metronidazole + Adalimumab | Intervention Type: DRUG; Name: Azathioprine; Assigned to Arm(s): Metronidazole + Azathioprine. | Intervention Type: DRUG; Name: Adalimumab; Assigned to Arm(s): Metronidazole + Adalimumab

Answer: A